Tsifran: analogues and comparative characteristics of drugs. The best analogue of "Tsifran": comparison of drugs and reviews
Drug name: CIFRAN(CIFRAN)
International name: ciprofloxacin (ciprofloxacin)
KFG: Antibacterial drug of the fluoroquinolone group
Owner reg. certificates: RANBAXY LABORATORIES Ltd. (India)
DOSAGE FORM, COMPOSITION AND PACKAGING:
10 pieces. - contour cellular packaging (1) - cardboard packs.
PHARMACHOLOGIC EFFECT Broad-spectrum antimicrobial agent of the fluoroquinolone group. Has a bactericidal effect. Suppresses DNA gyrase and inhibits bacterial DNA synthesis. Highly active against most gram-negative bacteria: Pseudomonas aeruginosa, Haemophilus influenzae, Escherichia coli, Shigella spp., Salmonella spp., Neisseria meningitidis, Neisseria gonorrhoeae. Active against Staphylococcus spp. (including strains that produce and do not produce penicillinase, methicillin-resistant strains), some strains of Enterococcus spp., Campylobacter spp., Legionella spp., Mycoplasma spp., Chlamydia spp., Mycobacterium spp. Ciprofloxacin is active against bacteria that produce beta-lactamases. Resistant to ciprofloxacin Ureaplasma urealyticum, Clostridium difficile, Nocardia asteroides. The effect against Treponema pallidum has not been sufficiently studied.
PHARMACOKINETICS
Rapidly absorbed from the gastrointestinal tract. Bioavailability after oral administration is 70%. Food intake has little effect on the absorption of ciprofloxacin. Plasma protein binding is 20-40%. Distributed in tissues and body fluids. Penetrates cerebrospinal fluid: concentrations of ciprofloxacin in non-inflamed meninges reach 10%, with inflammation - up to 37%. High concentrations are achieved in bile. Excreted in urine and bile.
INDICATIONS Infectious and inflammatory diseases caused by microorganisms sensitive to ciprofloxacin, incl. diseases respiratory tract, abdominal cavity and pelvic organs, bones, joints, skin; septicemia; severe infections of the ENT organs. Treatment of postoperative infections. Prevention and treatment of infections in patients with reduced immunity. For local application: acute and subacute conjunctivitis, blepharoconjunctivitis, blepharitis, bacterial corneal ulcers, keratitis, keratoconjunctivitis, chronic dacryocystitis, meibomitis. Infectious lesions eyes after injury or contact foreign bodies. Preoperative prophylaxis in ophthalmic surgery.
DOSING REGIME Individual. Orally - 250-750 mg 2 times a day. The duration of treatment is from 7-10 days to 4 weeks. For intravenous administration, a single dose is 200-400 mg, the frequency of administration is 2 times a day; Duration of treatment is 1-2 weeks, or more if necessary. Can be given intravenously as a bolus, but is more preferable drip administration within 30 min. When applied topically, instill 1-2 drops into the lower conjunctival sac of the affected eye every 1-4 hours. After the condition improves, the intervals between instillations can be increased. Maximum daily dose for adults when taken orally it is 1.5 g. SIDE EFFECT From the outside digestive system:
nausea, vomiting, diarrhea, abdominal pain, increased activity of liver transaminases, alkaline phosphatase, LDH, bilirubin, pseudomembranous colitis. From the side of the central nervous system: headache, dizziness, feeling tired, sleep disorders, nightmares, hallucinations, fainting, visual disturbances. From the urinary system: crystalluria, glomerulonephritis, dysuria, polyuria, albuminuria, hematuria, transient increase in serum creatinine. From the hematopoietic system: eosinophilia, leukopenia, neutropenia, changes in platelet count. From the side of cardio-vascular system:
tachycardia, disorders heart rate, arterial hypotension. Allergic reactions:
itchy skin, urticaria, Quincke's edema, Stevens-Johnson syndrome, arthralgia. Adverse reactions associated with chemotherapeutic effects: candidiasis. Local reactions:
pain, phlebitis (with intravenous administration). When using eye drops in some cases, mild soreness and hyperemia of the conjunctiva are possible. Others: vasculitis
CONTRAINDICATIONS
Pregnancy, lactation ( breast-feeding), children and adolescents under 15 years of age, hypersensitivity to ciprofloxacin and other quinolone drugs.
PREGNANCY AND LACTATION Contraindicated during pregnancy and lactation. Ciprofloxacin penetrates the placental barrier and is excreted breast milk. In experimental studies It has been found to cause arthropathy.
SPECIAL INSTRUCTIONS In patients with impaired renal function, dosage regimen adjustment is required. Use with caution in elderly patients, with atherosclerosis of cerebral vessels, disorders cerebral circulation, epilepsy, convulsive syndrome unknown etiology. During treatment, patients should receive sufficient fluids. In case of persistent diarrhea, ciprofloxacin should be discontinued. With simultaneous intravenous administration of ciprofloxacin and barbiturates, monitoring of heart rate, blood pressure, and ECG is necessary. During treatment, it is necessary to control the concentration of urea, creatinine, and liver transaminases in the blood. During treatment, a decrease in reactivity is possible (especially when used simultaneously with alcohol). Ciprofloxacin should not be administered subconjunctivally or directly into the anterior chamber of the eye.
DRUG INTERACTIONS With simultaneous use of ciprofloxacin with didanosine, the absorption of ciprofloxacin is reduced due to the formation of ciprofloxacin complexes with aluminum and magnesium buffers contained in didanosine. When used simultaneously with warfarin, the risk of bleeding increases. With the simultaneous use of ciprofloxacin and theophylline, it is possible to increase the concentration of theophylline in the blood plasma, increase T1/2 of theophylline, which leads to an increased risk of developing toxic effect associated with theophylline. Simultaneous use antacids, as well as drugs containing aluminum, zinc, iron or magnesium ions, can cause a decrease in the absorption of ciprofloxacin, so the interval between the administration of these drugs should be at least 4 hours.
| Release form | Price, rub. |
| Tsifran TB p/o 500 mg N10 | 71.80 |
| Tsifran TB p/o 250 mg N10 | 43.20 |
| Tsifran ST TB p/o 500/600 mg N10### | 249.60 |
| 261.20 | |
| 171.80 | |
| 271.30 rub. | |
| 171.10 rub. | |
| Tsifran tb p/o 250 mg N10 (RANBAXY (India) | 46.70 rub. |
| Tsifran ST tb p/o 500/600 mg N10 (RANBAXY (India) | 258.40 rub. |
| Tsifran TB p/o 500 mg N10 (RANBAXY (India) | 72.50 rub. |
| Cifran solution for infusion 200 mg/100 ml (RANBAXY (India) | 52.80 rub. |
| 270.30 rub. | |
| 178.40 rub. | |
| Cifran solution for infusion 200 mg/100ml (RANBAXY (India) | 54.70 rub. |
| Tsifran ST tab 500/600 mg N10 (RANBAXY (India) | 259.20 rub. |
| Cifran tab 250 mg N10 (RANBAXY (India) | 45.90 rub. |
| Tsifran tab 500 mg N10 (RANBAXY (India) | 74.80 rub. |
Analogues of Tsifran: |
|
| Alcipro | |
| Afenoxin | |
| Basijen | |
| Betaciprol | |
| Vero-Ciprofloxacin | |
| Zindolin 250 | |
| Ificipro | |
| Quintor | |
| Quintor TB p/o 0.5 N10### | 77.60 |
| Quintor TB p/o 0.25 N10### | 37.20 |
| Quipro | |
| Liproquin | |
| Microflox | |
| Oftocipro | |
| Procipro | |
| Recipro | |
| Syphlox | |
| Tseprova | |
| Ciloxane | |
| Tsipraz | |
| Tsiprinol | |
| Tsiprinol TB po 500 mg N10### | 94.90 |
| Tsiprinol amp conc. d/inf 10mg/1ml 10ml N5 KRKA### | 16.30 |
| Tsiprinol TB p/o 250 mg N10KRKA### | 59.70 |
| Tsiprinol amp conc. d/inf 10mg/1ml 10ml N1 KRKA (KRKA (Slovenia) | 16.30 rub. |
| Tsiprinol TB p/o 500 mg N10 (KRKA (Slovenia) | 102.60 rub. |
| Tsiprinol bottle. solution d/inf 2mg/ml 100ml N1 (KRKA (Slovenia) | 83.50 rub. |
| Tsiprinol amp conc. for infusion 10mg/1ml 10ml N1 KRKA (KRKA (Slovenia) | 19.20 rub. |
| Tsiprinol tab 500 mg N10 (KRKA (Slovenia) | 102.60 rub. |
| Tsiprinol bottle. solution for infusion 2 mg/ml 100 ml N1 (KRKA (Slovenia) | 83.50 rub. |
| Tsiprinol SR | |
| Tsiprobay | |
| Ciprobay TB 250mg N10 | 422.70 |
| Ciprobay TB 500mg N10 | 604.20 |
| Tsiprobay TB 250 mg N10 (BAYER (Germany) | 474.20 rub. |
| Tsiprobay TB 500 mg N10 (BAYER (Germany) | 664.20 rub. |
| Tsiprobay tab 250 mg N10 (BAYER (Germany) | 474.20 rub. |
| Tsiprobay tab 500 mg N10 (BAYER (Germany) | 636.00 rub. |
| Ciprobid | |
| Cyprobrine | |
| Ciprodox | |
| Ciprolacare | |
| Tsiprolet | |
| Tsiprolet TB 250mg N10 | 50.90 |
| Tsiprolet TB 500mg N10 | 93.90 |
| Tsiprolet ch. drops 3mg/ml 5ml | 50.70 |
| Tsiprolet A 600mg+500mg TB p/o N10 (Dr. REDDY"S Lab. (India) | 167.80 rub. |
| Tsiprolet ch. drops 3 mg/ml 5 ml (Dr. REDDY "S Lab. (India) | 52.90 rub. |
| Tsiprolet TB 250 mg N10 (Dr. REDDY "S Lab. (India) | 50.90 rub. |
| Tsiprolet TB 500 mg N10 (Dr. REDDY "S Lab. (India) | 95.60 rub. |
| Tsiprolet eye drops 3mg/ml 5ml (Dr. REDDY"S Lab. (India) | 55.40 rub. |
| Tsiprolet A 600mg+500mg tab N10 (Dr. REDDY"S Lab. (India) | 157.50 rub. |
| Tsiprolet tab 250 mg N10 (Dr. REDDY "S Lab. (India) | 54.10 rub. |
| Tsiprolet tab 500 mg N10 (Dr. REDDY "S Lab. (India) | 98.50 rub. |
| Ciprolone | |
| Tsipromed | |
| Tsipromed hl. drops 0.3% -5ml | 109.10 |
| Tsipromed ear drops 0.3%-10ml | 122.30 |
| Tsipromed hl. drops 0.3%-5ml (PROMED EXPORTS (India) | 119.60 rub. |
| Tsipromed ear drops 0.3%-10ml (PROMED EXPORTS (India) | 139.00 rub. |
| Tsipromed eye drops 0.3%-5ml (PROMED EXPORTS (India) | 118.00 rub. |
| Cypropane | |
| Tsiprosan | |
| Tsiprosin | |
| Ciprosol | |
| Ciprofloxabol | |
| Ciprofloxacin | |
| Ciprofloxacin TB po 500 mg N10 Ozone | 19.00 |
| Ciprofloxacin inf 2mg/ml 100ml###MHPP | 26.40 |
| Ciprofloxacin inf 2mg/ml 100ml### | 26.80 |
| Ciprofloxacin TB po 500 mg N10 FPO | 20.00 |
| Ciprofloxacin inf 2mg/ml 100ml (Sintez, Kurgan (Russia) | 25.70 rub. |
| Ciprofloxacin TB po 250 mg N10 Ozone (Ozone (Russia) | 10.60 rub. |
| Ciprofloxacin TB po 500 mg N10 Ozone (Ozone (Russia) | 22.10 rub. |
| Ciprofloxacin eye/ear drops 0.3% 5ml (ROMPHARM Comp. (Romania) | 32.30 rub. |
| Ciprofloxacin TB po 500 mg N10 FPO (Obolenskoye FP (Russia) | 20.40 rub. |
| Ciprofloxacin infusion 2 mg/ml 100 ml (Sintez, Kurgan (Russia) | 28.80 rub. |
| Ciprofloxacin tab 250mg N10 Ozone (Ozone (Russia) | 10.60 rub. |
| Ciprofloxacin tab 500mg N10 Ozone (Ozone (Russia) | 20.10 rub. |
| Ciprofloxacin tab 500mg N10 FPO (Obolenskoye FP (Russia) | 20.40 rub. |
| Ciprofloxacin Bufus | |
| Ciprofloxacin Sandoz | |
| Ciprofloxacin* | |
| Ciprofloxacin-AKOS | |
| Ciprofloxacin-Promed | |
| Ciprofloxacin-Teva | |
| Ciprofloxacin-FPO | |
| Ciprofloxacin hydrochloride | |
| Ciprofloxacin hydrochloride film-coated tablets, 0.25 g | |
| Citeral | |
| Cifloxinal | |
| Tsifran OD | |
| Tsifran OD TB prol.d-ya p/o 1000 mg N10 | 261.20 |
| Tsifran OD TB prol.d-ya p/o 500mg N10 | 171.80 |
| Tsifran OD TB prol.d-ya p/pl.about 1000 mg N10 (RANBAXY (India) | 271.30 rub. |
| Tsifran OD TB prol.d-ya p/pl.about 500 mg N10 (RANBAXY (India) | 171.10 rub. |
| Tsifran OD tab 1000 mg N10 (RANBAXY (India) | 270.30 rub. |
| Tsifran OD tab 500 mg N10 (RANBAXY (India) | 178.40 rub. |
| Ecotsifol | |
Source of information: Vidal Directory
In this article you can find instructions for use medicinal product Tsifran. Feedback from site visitors - consumers - is presented of this medicine, as well as the opinions of specialist doctors on the use of Tsifran in their practice. We kindly ask you to actively add your reviews about the drug: whether the medicine helped or did not help get rid of the disease, what complications were observed and side effects, perhaps not stated by the manufacturer in the annotation. Analogs of Tsifran if available structural analogues. Use for the treatment of sore throat and conjunctivitis in adults, children, as well as during pregnancy and breastfeeding.
Tsifrana- antimicrobial agent broad spectrum of action of the group of fluoroquinolones. Has a bactericidal effect. Suppresses DNA gyrase and inhibits bacterial DNA synthesis.
Highly active against most gram-negative bacteria: Pseudomonas aeruginosa, Haemophilus influenzae, Escherichia coli, Shigella spp., Salmonella spp., Neisseria meningitidis, Neisseria gonorrhoeae.
Active against Staphylococcus spp. (including strains that produce and do not produce penicillinase, methicillin-resistant strains), some strains of Enterococcus spp., Campylobacter spp., Legionella spp., Mycoplasma spp., Chlamydia spp., Mycobacterium spp.
Ciprofloxacin (the active ingredient of the drug Cifran) is active against bacteria that produce beta-lactamases.
Ureaplasma urealyticum, Clostridium difficile, and Nocardia asteroides are resistant to ciprofloxacin. The effect against Treponema pallidum has not been sufficiently studied.
Tinidazole is an antiprotozoal and antimicrobial agent, an imidazole derivative, effective against anaerobic microorganisms, such as Clostridium difficile, Clostridium perfringens, Bacteroides fragilis, Peptococcus and Peptostreptococcus anaerobius.
Pharmacokinetics
Rapidly absorbed from the gastrointestinal tract. Food intake has little effect on the absorption of Cifran. Plasma protein binding is 20-40%. Distributed in tissues and body fluids. Penetrates into the cerebrospinal fluid: concentrations of ciprofloxacin with non-inflamed meninges reach 10%, with inflamed meninges - up to 37%. High concentrations are achieved in bile. Excreted in urine and bile.
Indications
- infectious and inflammatory diseases caused by microorganisms sensitive to ciprofloxacin, incl. diseases of the respiratory tract, abdominal cavity and pelvic organs, bones, joints, skin; septicemia; severe infections of the ENT organs. Treatment of postoperative infections. Prevention and treatment of infections in patients with reduced immunity;
- for local use: acute and subacute conjunctivitis, blepharoconjunctivitis, blepharitis, bacterial corneal ulcers, keratitis, keratoconjunctivitis, chronic dacryocystitis, meibomitis. Infectious eye lesions after injury or foreign bodies. Preoperative prophylaxis in ophthalmic surgery.
Release forms
Film-coated tablets 250 mg and 500 mg (OD - prolonged action and ST - contains tinidazole).
Eye drops.
Solution for infusion (injections in injection ampoules).
Instructions for use and dosage regimen
Individual. Orally - 250-750 mg 2 times a day. The duration of treatment is from 7-10 days to 4 weeks.
For intravenous administration single dose - 200-400 mg, frequency of administration - 2 times a day; Duration of treatment is 1-2 weeks, or more if necessary. It can be administered intravenously as a bolus, but more preferably by drip (dropper) over 30 minutes.
When applied topically, instill 1-2 drops into the lower conjunctival sac of the affected eye every 1-4 hours. After the condition improves, the intervals between instillations can be increased.
The maximum daily dose for adults when taken orally is 1.5 g.
Side effect
- nausea, vomiting;
- diarrhea;
- stomach ache;
- pseudomembranous colitis;
- headache;
- dizziness;
- feeling tired;
- sleep disorders;
- nightmares;
- hallucinations;
- fainting;
- visual disturbances;
- glomerulonephritis;
- dysuria;
- polyuria;
- albuminuria;
- hematuria;
- eosinophilia, leukopenia, neutropenia, changes in platelet count;
- tachycardia;
- heart rhythm disturbances;
- arterial hypotension;
- skin itching;
- hives;
- Quincke's edema;
- Stevens-Johnson syndrome;
- candidiasis;
- vasculitis;
- phlebitis (with intravenous administration);
- mild soreness and hyperemia of the conjunctiva (eye drops).
Contraindications
- pregnancy;
- lactation (breastfeeding);
- childhood and adolescence up to 15 years;
- hypersensitivity to ciprofloxacin and other quinolone drugs.
Use during pregnancy and breastfeeding
Cifran penetrates the placental barrier and is excreted in breast milk. Use during pregnancy or breastfeeding is undesirable.
special instructions
In patients with impaired renal function, dosage regimen adjustment is required. Use with caution in elderly patients, with atherosclerosis of cerebral vessels, cerebrovascular accidents, epilepsy, and convulsive syndrome of unknown etiology.
During treatment, patients should receive sufficient fluids.
In case of persistent diarrhea, Cifran should be discontinued.
With simultaneous intravenous administration of ciprofloxacin and barbiturates, monitoring of heart rate, blood pressure, and ECG is necessary. During treatment, it is necessary to control the concentration of urea, creatinine, and liver transaminases in the blood.
During treatment, a decrease in reactivity is possible (especially when used simultaneously with alcohol).
It is not allowed to administer Cifran subconjunctivally or directly into the anterior chamber of the eye.
Drug interactions
With simultaneous use of ciprofloxacin with didanosine, the absorption of ciprofloxacin is reduced due to the formation of ciprofloxacin complexes with aluminum and magnesium buffers contained in didanosine.
When used simultaneously with warfarin, the risk of bleeding increases.
With the simultaneous use of Cifran and theophylline, it is possible to increase the concentration of theophylline in the blood plasma, increase T1/2 of theophylline, which leads to an increased risk of developing toxic effects associated with theophylline.
Simultaneous use of antacids, as well as drugs containing aluminum, zinc, iron or magnesium ions, can cause a decrease in the absorption of ciprofloxacin, so the interval between the administration of these drugs should be at least 4 hours.
Analogues of the drug Tsifran
Structural analogues of the active substance:
- Alcipro;
- Afenoxin;
- Basijen;
- Betaciprol;
- Vero-Ciprofloxacin;
- Zindolin 250;
- Ificipro;
- Quintor;
- Quipro;
- Liproquin;
- Microflox;
- Oftocipro;
- Procipro;
- Recipro;
- Siphlox;
- Tseprova;
- Ciloxane;
- Cypraz;
- Tsiprinol;
- Ciprobay;
- Ciprobid;
- Cyprobrine;
- Ciprodox;
- Ciprolacare;
- Tsiprolet;
- Ciprolone;
- Tsipromed;
- Cypropane;
- Tsiprosan;
- Cyprosyn;
- Ciprosol;
- Ciprofloxabol;
- Ciprofloxacin;
- Citeral;
- Cifloxinal;
- Tsifran OD;
- Tsifran ST;
- Ecotsifol.
If there are no analogues of the drug for the active substance, you can follow the links below to the diseases for which the corresponding drug helps, and look at the available analogues for the therapeutic effect.
Cifran is medication with antimicrobial action. It is used to treat a wide range of diseases, the development of which is caused by pathogenic microorganisms.
The antibiotic demonstrates high rates of effectiveness in the fight against microbes sensitive to Ciprofloxacin.
Available in tablet form of 100, 250, 500, 600 mg, as well as in the form of a solution for preparing a suspension.
Prescribed by a specialized specialist to those patients who have been diagnosed various kinds infectious diseases and inflammatory in nature V different organs and fabrics. Precisely because such diseases are provoked by microorganisms sensitive to Ciprofloxacin, the drug helps to quickly eliminate the problem. The wide range of capabilities of Tsifran allows it to be used for large list diseases. Namely:
- ARVI, loringitis, pharyngitis, otitis, cystitis, prostatitis;
- infections that appeared after gynecological interventions, operations, childbirth;
- acute poisoning, gastrointestinal diseases;
- sepsis and peritonitis, as a consequence surgical operations, injuries;
- dermatological diseases and so on.
In addition, Cifran is used as a prophylactic and therapy for patients who have reduced immunity and low ability of the body to resist infections.
Cifran is taken after the patient has eaten. You need to take a pill big amount of water, swallowing whole, without chewing or biting.
note
The dose selection of this medicinal product should be qualified specialist, taking into account the patient’s body weight, the level of sensitivity of bacteria to the effects of the components of the drug, the nature of the disease and the degree of its neglect.
The course of therapy can last from 7 to 14 days in a row. And only in special cases complex case the patient may need a longer course of treatment.
Analogues of Tsifran domestic and foreign production the most popular today are:
- Alcipro has an antimicrobial effect on the patient's body. Characterized by wide range action and high efficiency in eliminating bacteria both in the resting phase and in the active reproduction phase.
- Afenoxin is highly effective in the treatment of a wide range of diseases caused by pathogenic microbes.
- Basijen is used to quickly kill bacterial cells of a pathogenic nature in the patient’s body.
- Betaciprol is created for the treatment of patients diagnosed with bacterial diseases.
- Vero-Ciprofloxacin.
- Zindolin 250x.
- Ificipro and others.
All these drugs have a similar effect on the patient’s body due to the use of the same basic components in their production - ciprofloxacin, which instantly deactivates multiplying pathogenic microorganisms, as well as bacteria in the resting phase.
Tsifran in different pharmacies across the Russian Federation costs between 400-1000 rubles. The cheapest drugs that have a similar effect on the body to Cifran, but are much cheaper, are:
- Tsiprolet - 100-400 rubles;
- Tsifran ST - 300-500 rubles.
Amoxiclav or Tsifran: which is better?
- Amoxiclav is a combined antibacterial drug, available not only in the form of tablets, but also as a suspension. It contains clavulanic acid, so treatment with this drug is easier to tolerate by the patient’s body.
- However, Tsifran is the only one oral medication with antipseudomonas activity. Therefore, it is more effective in treating acute forms infectious diseases advanced bacterial infections.
- We also note that Tsifran demonstrates high efficiency for the treatment of elderly patients.
If you perform a comparative description of another analogue of Tsifran in terms of therapeutic effect, you can come to the following conclusions: Tsiprolet is available in the form of tablets, injection solution and eye drops.
Both drugs are antibiotics used to treat various types of infections, however, Tsiprolet belongs to the second generation antibiotics and is better tolerated by patients with gastrointestinal problems.
This drug is prescribed to combat infectious and bacterial diseases.
It is worth noting
Cifran is best taken by those patients who suffer from gastrointestinal diseases. After all, Cifran ST has virtually no effect on the microflora in the human intestine, thereby not provoking bacterial candidiasis and vaginal vaginosis in representatives of the fairer sex of humanity.
Dysbacteriosis does not develop while taking it, but the effectiveness of treatment is quite high. The effect lasts for 12 hours after taking the tablet.
Cifran and Ciprofloxacin have exactly the same effect on the human body. These drugs are interchangeable, that is, if it is impossible to get one of them, it can be replaced with an analogue. Both drugs are highly effective in combating many diseases. For example, they are used in therapy chronic sinusitis or sinusitis.
Both Cifran and Ciprofloxacin are used in the treatment of adult patients. They are not prescribed for children under 6 years of age; the course of treatment is selected individually for each specific patient and can be adjusted during the admission process.
Tsifran and Tsifran ST: differences in drugs in therapeutic action and composition
Tsifran ST is combination drug, made on the basis of tinidazole.
The product is characterized by antiprotozoal and antibacterial properties.
This is an antibiotic that effectively eliminates gram-positive and gram-negative anaerobic microorganisms.
Tsifran and Tsifran ST are very similar in composition and effect on the patient.
However, they also have their differences: the latter is used in cases of illness caused specifically by gram-negative bacteria and demonstrates a wider spectrum of action.
Cifran (ciprofloxacin) - antibacterial drug fluoroquinolone series. Exhibits a bactericidal effect. Compliance (adherence to treatment) is one of the most current problems modern medicine. Proper compliance is ensured by a number of factors, including: taking the drug together before, with or after meals, dosing frequency 1 time per day, good tolerability and oral route introduction. Considering that the effectiveness of antibacterial drugs largely depends on the regularity and timeliness of their administration, the creation medicines, which could be taken once a day, has a particularly important. Insufficient compliance can lead to such undesirable consequences as recurrence of the disease or its more severe course, the development of complications, increased cost of treatment, the need to admit the patient to a hospital, the emergence of drug-resistant pharmacological effects bacterial strains. Digital from Indian pharmaceutical company"Ranbaxy" - innovative antibiotic long-acting, which is sufficient to take once a day. The purpose of its creation was maximum compliance. This task was complicated by the fact that ciprofloxacin is absorbed only in a limited area of the duodenum, not exceeding 20–30 cm in length. It was necessary to develop a technology that would prevent the drug from being removed from the gastrointestinal tract until the tablet is completely dissolved. It took 7 years to develop Cifran. The drug uses Float Erode Diffusion Technology, which allows the tablet to remain in the stomach for a long time. The basis dosage form is represented by a matrix that provides layer-by-layer release of ciprofloxacin into the gastric lumen.
Introduced into the composition of the drug Excipients, interacting with the acidic contents of the stomach, push the tablet onto its surface, thereby preventing its premature evacuation. Cifran has a wide therapeutic range, covering microorganisms such as coli, Klebsiella, Salmonella, Proteus, Shigella, Yersinia, Enterobacter, Morganella, Vibrio cholerae, Serratia, Pseudomonas, Neisseria, Moraxella, Gardnerella, Helicobacter, Staphylococcus, Streptococcus, Listeria, etc. The drug is highly effective in the treatment of infections both acute and chronic phase, incl. in cases of persistence of slowly growing microorganisms with slow metabolism in infectious foci. Cifran acts on pathogens resistant to other antibiotics: aminoglycosides, cephalosporins, etc. It is not characterized by the phenomenon of cross stability and hypersensitivity to other antibacterial drugs. Cifran has good pharmacokinetic characteristics, incl. high bioavailability, optimal distribution in organs and tissues, long half-life. Tsifran is particularly effective in the treatment of infections of the urogenital tract. Because The active component of the drug is 40–50% excreted by the kidneys in its original form, high concentrations are created in the urine, which ensures a pronounced bactericidal effect and clinical effectiveness. In patients with renal failure correction of the dosage regimen downward is required. During the medication course, patients need to consume sufficient amounts of water. Alcohol is contraindicated during treatment.
Pharmacology
Broad-spectrum antimicrobial agent of the fluoroquinolone group. Has a bactericidal effect. Suppresses DNA gyrase and inhibits bacterial DNA synthesis.
Highly active against most gram-negative bacteria: Pseudomonas aeruginosa, Haemophilus influenzae, Escherichia coli, Shigella spp., Salmonella spp., Neisseria meningitidis, Neisseria gonorrhoeae.
Active against Staphylococcus spp. (including strains that produce and do not produce penicillinase, methicillin-resistant strains), some strains of Enterococcus spp., Campylobacter spp., Legionella spp., Mycoplasma spp., Chlamydia spp., Mycobacterium spp.
Ciprofloxacin is active against bacteria that produce β-lactamases.
Ureaplasma urealyticum, Clostridium difficile, and Nocardia asteroides are resistant to ciprofloxacin. The effect against Treponema pallidum has not been sufficiently studied.
Pharmacokinetics
Rapidly absorbed from the gastrointestinal tract. Bioavailability after oral administration is 70%. Food intake has little effect on the absorption of ciprofloxacin. Plasma protein binding is 20-40%. Distributed in tissues and body fluids. Penetrates into the cerebrospinal fluid: concentrations of ciprofloxacin with non-inflamed meninges reach 10%, with inflamed meninges - up to 37%. High concentrations are achieved in bile. Excreted in urine and bile.Release form
10 pieces. - contour cellular packaging (1) - cardboard packs.
10 pieces. - contour cell packaging (10) - cardboard packs.
10 pieces. - contour cell packaging (100) - cardboard packs.
10 pieces. - aluminum contour cellular packaging (1) - cardboard packs.
10 pieces. - aluminum contour cellular packaging (10) - cardboard packs.
Dosage
Individual. Orally - 250-750 mg 2 times a day. The duration of treatment is from 7-10 days to 4 weeks.
For intravenous administration, a single dose is 200-400 mg, the frequency of administration is 2 times a day; Duration of treatment is 1-2 weeks, or more if necessary. It can be administered intravenously as a stream, but drip administration over 30 minutes is more preferable.
When applied topically, instill 1-2 drops into the lower conjunctival sac of the affected eye every 1-4 hours. After the condition improves, the intervals between instillations can be increased.
The maximum daily dose for adults when taken orally is 1.5 g.
Interaction
With simultaneous use of ciprofloxacin with didanosine, the absorption of ciprofloxacin is reduced due to the formation of ciprofloxacin complexes with aluminum and magnesium buffers contained in didanosine.
When used simultaneously with warfarin, the risk of bleeding increases.
With the simultaneous use of ciprofloxacin and theophylline, it is possible to increase the concentration of theophylline in the blood plasma, increase T1/2 of theophylline, which leads to an increased risk of developing toxic effects associated with theophylline.
Simultaneous use of antacids, as well as drugs containing aluminum, zinc, iron or magnesium ions, can cause a decrease in the absorption of ciprofloxacin, so the interval between the administration of these drugs should be at least 4 hours.
Side effects
From the digestive system: nausea, vomiting, diarrhea, abdominal pain, increased activity of liver transaminases, alkaline phosphatase, LDH, bilirubin, pseudomembranous colitis.
From the side of the central nervous system: headache, dizziness, feeling of fatigue, sleep disorders, nightmares, hallucinations, fainting, visual disturbances.
From the urinary system: crystalluria, glomerulonephritis, dysuria, polyuria, albuminuria, hematuria, transient increase in serum creatinine.
From the hematopoietic system: eosinophilia, leukopenia, neutropenia, change in platelet count.
From the cardiovascular system: tachycardia, heart rhythm disturbances, arterial hypotension.
Allergic reactions: skin itching, urticaria, Quincke's edema, Stevens-Johnson syndrome, arthralgia.
Adverse reactions associated with chemotherapy: candidiasis.
Local reactions: pain, phlebitis (with intravenous administration). When using eye drops, in some cases, mild soreness and hyperemia of the conjunctiva are possible.
Other: vasculitis.
Indications
Infectious and inflammatory diseases caused by microorganisms sensitive to ciprofloxacin, incl. diseases of the respiratory tract, abdominal cavity and pelvic organs, bones, joints, skin; septicemia; severe infections of the ENT organs. Treatment of postoperative infections. Prevention and treatment of infections in patients with reduced immunity.
For local use: acute and subacute conjunctivitis, blepharoconjunctivitis, blepharitis, bacterial corneal ulcers, keratitis, keratoconjunctivitis, chronic dacryocystitis, meibomitis. Infectious eye lesions after injury or foreign bodies. Preoperative prophylaxis in ophthalmic surgery.
Use for renal impairment
In patients with impaired renal function, dosage regimen adjustment is required.Use in children
Contraindicated in children and adolescence up to 15 years.
Use in elderly patients
Use with caution in elderly patients.special instructions
In patients with impaired renal function, dosage regimen adjustment is required. Use with caution in elderly patients, with atherosclerosis of cerebral vessels, cerebrovascular accidents, epilepsy, and convulsive syndrome of unknown etiology.
During treatment, patients should receive sufficient fluids.
In case of persistent diarrhea, ciprofloxacin should be discontinued.
With simultaneous intravenous administration of ciprofloxacin and barbiturates, monitoring of heart rate, blood pressure, and ECG is necessary. During treatment, it is necessary to control the concentration of urea, creatinine, and liver transaminases in the blood.
During treatment, a decrease in reactivity is possible (especially when used simultaneously with alcohol).
Ciprofloxacin should not be administered subconjunctivally or directly into the anterior chamber of the eye.
Article rating
Tsifran is a popular imported antibiotic with a wide spectrum of action, used in practical medicine to treat infectious and inflammatory processes caused by susceptible microbes. The active ingredient is ciprofloxacin.
The product is available in several forms. Tablets are available in three names, a simple form - Tsifran and its improved analogues Tsifran OD and Tsifran ST. From the article you can learn about the features of the drug and analogues, their differences, advantages and disadvantages, figuring out what is best to use in what cases. It compares cheap and expensive drugs: Tsiprolet, Ciprofloxacin and Tsiprobay
Tsiprolet
Tsiprolet is an antibacterial drug belonging to the group of fluorinated quinolones. This is generic ciprofloxacin, equal in effectiveness to the original drug.
Release form
The drug for systemic use is produced in the form of tablets and infusion solution, which is a colorless clear liquid. The oral form is produced in two versions:
- Tsiprolet - tablets contain 250 or 500 milligrams of the active ingredient;
- Ciprolet A is a combined antimicrobial and antiprotozoal medicine that contains two active ingredients: 500 mg of ciprofloxacin and 600 mg of tinidazole.
Indications
Tsiprolet is indicated for use in diseases of an infectious-inflammatory nature:
- acute lesions of the respiratory system;
- ENT organs;
- urinary system;
- biliary organs;
- intestines;
- bones, periosteum, joints;
- lesions of the skin and soft tissues;
- sexually transmitted diseases (gonorrhea, chlamydia).
The infusion form is used for sepsis, inflammation of the peritoneum and after surgery.
The drug is not used in the following cases:
- pregnancy;
- during breastfeeding;
- in childhood;
- allergies to the active substance and auxiliary components of the drug;
- severe pathology with impaired liver and kidney function.
Tsiprolet has photosensitizing properties, so you should spend less time in the sun while taking it.
Similarities and differences between drugs
Tsifran and Tsiprolet differ only in additional components, active ingredients in identical release forms are contained in equal quantities. But the available tablet version of Tsiprolet does not completely replace the prolonged form - Tsifran OD. Research has found that treatment with extended-release tablets more often ensures the complete destruction of pathogenic microbes in diseases of the respiratory system and urinary tract. In recent European recommendations on treatment urological diseases in the treatment of pyelonephritis and cystitis, the use of tablet preparations with a slow release of the active substance is indicated.
Replacing the Cifran OD tablet with a modified release of the active ingredient with the classic form reduces the convenience of dosing and contributes to a decrease in the effectiveness of antibiotic therapy
When comparing drugs Tsifran or Tsiprolet - which is better, you need to take into account that their strength antimicrobial action confirmed clinical studies and is the same. They have identical indications and are used to treat the same conditions. These medications are interchangeable, with the exception of extended-release tablets. The main factor for choosing is their availability, since the price differs slightly, and reviews of patients who took Tsifran or Tsiprolet indicate good action both.
Ciprofloxacin
Ciprofloxacin is a domestically produced medicine, its price is the most affordable among the drugs described. This medicine is used in the treatment of infectious and inflammatory diseases caused by susceptible microorganisms.
Release form
The drug is produced in the form of tablets of 0.25, 0.5 and 0.75 grams and a solution for infusion in bottles of 100 and 200 milliliters.
Indications
Indications for the use of Ciprofloxacin are the following infectious and inflammatory diseases:
- ENT infections.
- infectious diseases of the respiratory tract.
- infections urinary organs: cystitis, pyelonephritis.
- infectious diseases of the digestive system: biliary tract and gallbladder, intestinal infections, (dysentery, salmonellosis, cholera);
- infections of bones (including teeth), periosteum, joints;
- infections of the pelvic organs and genitals (prostatitis, paraproctitis, colpitis);
- and neonatal infections;
- infectious lesions of the skin, mucous membranes and soft tissues;
- sepsis, purulent peritonitis;
- infectious diseases in immunodeficiency.
Contraindications and features of use
Ciprofloxacin should not be used in the following cases:
- intolerance to ciprofloxacin or other fluoroquinolones;
- age under 16 years;
- pregnancy and breastfeeding.
Situations requiring careful monitoring and caution when using the drug:
- pathology of the central nervous system;
- mental disorders;
- liver and kidney failure;
- old age.
Similarities and differences between analogues
Domestic medicines have a much lower cost compared to imported ones. But the effect of cheap medicine is not always equal to action the first sample of the active ingredient. Drugs that have not undergone rigorous equivalence studies may not always provide the required strength. antimicrobial action. And although negative reviews he has more, Ciprofloxacin - real alternative expensive medicines. This is a substitute for Tsifran, which costs almost 5 times less.
Tsiprobay
It is the most studied of the listed drugs, produced in Germany by the Bayer company, which first synthesized active ingredient drug. It is produced in all forms, including extended-release tablets, but they are not supplied to Russia. Therefore, the analogue for the drug Cifran OD can only be purchased abroad. Russian pharmacies offer the medicine in the form of tablets of 250 or 500 mg and a solution for infusion with 200 mg of the active ingredient in one bottle.
pharmachologic effect
The use of Tsiprobay leads to disruption of DNA structuring, interfering with the functioning and reproduction of microorganisms. The instructions note that the medication is used in the treatment of diseases caused by gram-negative microbes (Klebsiella, Escherichia, Shigella, Salmonella). Some gram-positive bacteria - staphylococci and streptococci - are also susceptible to it.
Method of application, dosage regimen
Tsiprobay tablets are usually prescribed 500 mg twice a day, maximum 1500 mg per day. The 250 mg dosage is rarely used; the only indication for its use is cystitis. The infusion form is used in daily dose 800 mg for 2-3 injections.
Similarities and differences between drugs
Tsiprobay is suitable for replacing Tsifran in the appropriate release forms, since it is a reference drug.
Instructions for use are almost identical for both medications. Manufacturers of Tsifran practically copied it from Tsiprobay, replacing the name. Indications, contraindications, prescription patterns and features of use are the same.
According to reviews, the drug is characterized by rapid action and high antibacterial activity. But taking into account the fact that the price of Tsiprobay is the highest, it makes sense to use it as a replacement only in the absence of Tsifran or other necessary medicine.
Conclusion
Range of medicines registered in the domestic pharmaceutical market, makes it easy to replace Tsifran and Tsifran ST with analogues. Although the composition of the drugs is the same, replacing them does not always provide the same ease of use and results of use. Antibiotics are among the drugs prescription, so if there is no prescribed option, consult your doctor.
